Regenerative Medical Technology Group Stock Price, News & Analysis

Regenerative Medical Technologies Group, Inc. (RMTG) is a regenerative medicine company that operates through its wholly owned subsidiary Global Stem Cells Group (GSCG). The company focuses on stem cell and cellular therapies, regenerative biologics, and physician education, and trades on the over-the-counter market under the symbol RMTG. Through a network that spans more than 30 countries, RMTG combines clinical operations, product and equipment distribution, manufacturing capabilities, and medical training to participate in the expanding global regenerative medicine market.

According to company disclosures, RMTG generates revenue from four main channels: product sales, equipment sales, patient procedures, and physician training. In addition, it has introduced a turnkey exclusive membership model in which new members pay upfront fees for assistance in setting up regenerative medicine clinics, along with ongoing training and support, and commit to purchasing supplies exclusively from RMTG. These activities are conducted primarily through GSCG and its educational arm, the International Society for Stem Cell Application (ISSCA).

Business Model and Operating Structure

RMTG describes itself as a regenerative medicine company offering diverse products and services through GSCG. GSCG is characterized as an international consortium of regenerative medicine entities that includes clinics, laboratories, academic institutions, and product distributors. The company reports that it distributes stem cells and other regenerative-based cell lines and equipment internationally, and that it specializes in education and training for physicians in regenerative medicine and cellular therapies.

The company’s integrated model links several activities:

• Clinical operations and procedures conducted through its network of clinics and affiliates.
• Product and equipment distribution, including stem cells and regenerative-based cell lines, and related devices.
• Medical education and certification through ISSCA, which organizes training events, workshops, and summits.
• Manufacturing of regenerative biologics through its CELLGENIC brand and associated facilities.

RMTG reports that sales are derived from its four main revenue channels, and that its affiliate and membership programs add additional revenue through upfront membership fees, ongoing support arrangements, and exclusive supply agreements.

Global Stem Cells Group and ISSCA Platform

Global Stem Cells Group is described as an international organization with a presence across multiple continents, operating clinics, research facilities, and training centers. It focuses on advancing cellular medicine and regenerative therapies by integrating scientific research, physician training, and product development. GSCG seeks to support every stage of regenerative practice, from laboratory innovation to clinical application.

ISSCA, the educational and scientific arm of GSCG, is presented as a multidisciplinary, physician-led community dedicated to training physicians in regenerative medicine and cellular therapies. The company states that ISSCA has more than 15 years of experience promoting education, research, and certification through international summits, academic programs, and clinical alliances. ISSCA organizes global and regional events, including summits and in-country training programs, where physicians receive theoretical instruction, hands-on workshops, and certification in regenerative medicine protocols.

CELLGENIC Brand and Manufacturing Capabilities

RMTG’s CELLGENIC brand is described as offering a portfolio of regenerative medicine products that includes exosomes, mesenchymal stem cells (MSCs), natural killer (NK) cells, and platelet-rich plasma (PRP) kits. These products are associated with applications in orthopedics, neurology, pain management, aesthetic medicine, and longevity-focused therapies, as described in company communications.

The company has announced an advanced cell therapy manufacturing facility in Cancún, Mexico, operated through its CELLGENIC subsidiary. This facility is reported to be licensed by Mexico’s federal health authority COFEPRIS to operate as both a stem cell collection center and stem cell bank. The laboratory is described as having ISO-classified cleanrooms, cryopreservation systems, GMP-aligned workflows, and digital batch traceability systems. It is intended to support the manufacture, preservation, and distribution of human cellular products and to serve physicians, clinics, and scientific partners within the applicable regulatory framework.

The Cancún facility also includes designated areas for physician education programs delivered through ISSCA, allowing the company to integrate manufacturing with training and certification activities. Company statements indicate that the facility is expected to function as a base for responsible and scalable regenerative medicine infrastructure and to support a decentralized production strategy.

Global Network and Affiliate Model

RMTG reports a global footprint spanning more than 30 countries, with an affiliate and clinic network that includes multiple regions in Latin America, the Caribbean, and other international markets. Through its Global Stem Cells Group subsidiary, the company appoints regional representatives and affiliates who develop local distribution networks, training programs, and clinical partnerships.

The company’s affiliate program involves new members paying upfront membership fees, described as being in the six-figure dollar range, in exchange for turnkey assistance in establishing regenerative medicine clinics. These affiliates receive physician training through ISSCA, ongoing clinical support, marketing assistance, and access to regenerative medicine protocols. Affiliates are described as being required to purchase supplies exclusively from RMTG, which creates recurring product revenue in addition to initial membership fees.

RMTG has highlighted expansions into territories such as Puerto Rico, northern Argentina and Paraguay, Brazil, and the Dominican Republic through representation and affiliate agreements. These arrangements typically involve local medical leaders or organizations who act as official representatives for ISSCA, CELLGENIC, and GSCG initiatives in their respective markets, overseeing education programs, product distribution, and development of regenerative medicine centers.

Education, Events, and Training Revenue

Education and training are central to RMTG’s business model. Through ISSCA, the company organizes events such as global summits, regional conferences, and in-country training sessions. These events generate revenue through registration fees, certification programs, exhibitor opportunities, and product sales. Company communications describe events that include scientific lectures, hands-on workshops, and live clinical practice, with physicians completing certification by working through clinical cases under expert guidance.

RMTG has reported that its events attract participants from numerous countries and that ISSCA is regarded within the company’s materials as one of the largest organizations dedicated to training physicians in regenerative medicine. The company positions these events as a means of expanding its education platform, supporting affiliate development, and promoting its CELLGENIC product line as an official sponsor at certain trainings.

Clinical and Sports Medicine Partnerships

In addition to its education and affiliate activities, RMTG has announced a partnership with Bare Knuckle Fighting Championship (BKFC) to serve as the league’s official stem cell and regenerative medicine provider for treating fighters’ sport-related injuries. Company statements describe this collaboration as focused on providing stem cell and regenerative treatments aimed at supporting recovery, addressing pain, and preserving joint health for combat sports athletes. The partnership is also characterized as a way to increase awareness of regenerative medicine within professional athletics.

Regulatory Filings and Reporting

Regenerative Medical Technology Group Inc. is an SEC-reporting company with file number 000-56010. In a Form NT 10-Q, the company reported that it was unable, without unreasonable effort or expense, to timely compile all information required for its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The notification states that the company expects to file the report within the five-day grace period provided by SEC rules and indicates that no significant change in results of operations from the corresponding period of the prior year is anticipated for that filing.

The company has also issued press releases summarizing its financial performance, including year-over-year sales growth and operating income. These communications note that sales have been derived from product sales, equipment sales, patient procedures, and training, and that the company has maintained gross margins within a stated range while increasing revenues and operating income. Investors are directed in those releases to review the company’s filings on the SEC’s EDGAR system for detailed financial information.

Sector and Industry Context

RMTG operates in the biotechnology industry within the broader healthcare sector, with a focus on regenerative medicine and cellular therapies. Its activities encompass the distribution of stem cells and regenerative-based cell lines, operation of clinics and training centers, and manufacturing of biologic products. The company’s emphasis on physician education, certification, and global affiliate development reflects a model that links scientific training with clinical adoption and product utilization.

FAQs